Trial Profile
Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 Jul 2023
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary)
- Indications Ankylosing spondylitis; Autoimmune hepatitis; Behcet's syndrome; Cholangitis; Crohn's disease; Granulomatosis; Granulomatosis with polyangiitis; Idiopathic thrombocytopenic purpura; Primary sclerosing cholangitis; Psoriasis; Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus; Systemic scleroderma; Takayasu syndrome; Ulcerative colitis
- Focus Therapeutic Use
- Acronyms TRANSREG
- 03 Jun 2023 Results presented at the 24th Annual Congress of the European League Against Rheumatism
- 19 Jul 2021 Status changed from active, no longer recruiting to completed.
- 17 Aug 2020 Planned End Date changed from 20 Feb 2022 to 31 Mar 2021.